Recent Quotes
My Watchlist
Indicators
Local Stocks
Local Stocks
Energy Stocks
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Ligand Pharm (NQ: LGND )

142.62 USD +7.73 (+5.73%)
Official Closing Price Updated: 7:44 PM EST, Jan 22, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Ligand Pharm

< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Ligand Reports Second Quarter 2020 Financial Results
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three and six months ending June 30, 2020 and provided an operating forecast and program updates. Ligand... 
From Business Wire News Releases
Ligand’s Second Quarter Financial Results to be Reported August 3rd
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) provided today details of its plans to report second quarter 2020 financial results on August 3, 2020. Ligand’s CEO John Higgins, President and COO... 
From Business Wire News Releases
Functional, Human Antibodies Targeting SARS-CoV-2 Discovered Using IPA's Proprietary B cell Select™ and Single Step Cloning Hybridoma Technologies
From PR Newswire
Sermonix Pharmaceuticals to Collaborate With Eli Lilly and Company in Studying Combination of Lasofoxifene and Lilly’s CDK 4 and 6 Inhibitor, Abemaciclib, in Metastatic Breast Cancer
The multicenter Phase 2 trial, Sermonix’s Evaluation of Lasofoxifene and Abemaciclib in ESR1 Mutations, is projected to begin enrollment in Q3 2020. 
From GlobeNewswire News Releases
IPA Confirms Discovery of Fully Human, Potent, Neutralizing Antibodies Targeting SARS-CoV-2
From PR Newswire
Sermonix to Present Poster on Lasofoxifene, CDK 4/6 Inhibitor Combination for AACR Virtual Annual Meeting
University of Chicago preclinical study compared combination to that of fulvestrant and palbociclib in a mouse intraductal model with cells carrying Y537S ESR1 mutations. Findings will be shared June... 
From GlobeNewswire News Releases
Ligand Announces an Expansion of Vernalis Collaboration with Servier for Research on Novel Oncology Targets
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that Vernalis Research, a Ligand company, has expanded its oncology research collaboration with Servier, an international pharmaceutical... 
From Business Wire News Releases
Ligand CEO Issues Letter to Captisol Customers
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that Chief Executive Officer John Higgins issued a letter to Ligand’s Captisol® customers. The full text of that letter is as follows: 
From Business Wire News Releases
Ligand Announces Icagen’s Expansion of Collaboration with Roche to Develop and Commercialize Therapies for Neurological Diseases
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) and Icagen, a Ligand Company, announced today the expansion of Icagen’s license agreement with Roche to develop and commercialize small molecule ion... 
From Business Wire News Releases
Ligand Earns $3 Million Milestone Payment from Palvella Therapeutics
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces it has earned a $3 million milestone payment from Palvella Therapeutics as a result of Palvella raising $45 million in an oversubscribed... 
From Business Wire News Releases
Palvella Therapeutics Completes $45 Million Series C Financing
From GlobeNewswire News Releases
Ligand Reports First Quarter 2020 Financial Results
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three months ended March 31, 2020 and provided an operating forecast and program updates. Ligand management... 
From Business Wire News Releases
Ligand’s First Quarter Financial Results to be Reported May 6th
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) provided today details of its plans to report first quarter 2020 financial results on May 6, 2020. Ligand’s CEO John Higgins, President and COO Matt... 
From Business Wire News Releases
ImmunoPrecise Provides Updates on B Cell Select™ and Deep Display™ Programs for SARS-CoV-2 Antibody Discovery
From PR Newswire
Ligand Provides a Corporate Update and Announces May 6th as the Date for First Quarter Earnings Call
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) provides a general corporate update, as follows: 
From Business Wire News Releases
Ligand Completes Acquisition of Icagen Core Assets, Partnered Programs and Ion Channel Technologies
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces the completion of its acquisition of the core assets of Icagen’s North Carolina operations. As previously announced, the purchase price was... 
From Business Wire News Releases
Thinking about trading options or stock in Apple, Clorox, Electronic Arts, Ligand Pharmaceuticals, or Teladoc Health?
InvestorsObserver issues critical PriceWatch Alerts for AAPL, CLX, EA, LGND, and TDOC. 
From PR Newswire
Ligand’s Presentation at the Barclays Global Healthcare Conference Now a Webcast Only, New Slides Available on Ligand.com
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that today’s scheduled in-person presentation at the Barclays Global Healthcare Conference in Miami Beach was changed by conference... 
From Business Wire News Releases
Ligand Pharmaceuticals Management to Present at Two Investor Conferences in March
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that senior management will present at two upcoming investor conferences. 
From Business Wire News Releases
Ligand Raises 2020 Financial Guidance Due to Higher Captisol Material Sales
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces an update to its financial outlook and raises its 2020 financial guidance. Ligand now expects 2020 total revenues to be approximately $133... 
From Business Wire News Releases
INVESTOR ALERT: BDX LGND LOPE SBT: Kirby McInerney LLP Continues Investigation of Shareholder Claims
From GlobeNewswire News Releases
Ligand Agrees to Acquire Core Assets, Partnered Programs and Ion Channel Technologies from Icagen
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces the signing of an agreement whereby Ligand will acquire the core assets of Icagen, Inc.’s North Carolina operations, including partnered... 
From Business Wire News Releases
Ligand Reports Fourth Quarter and Full Year 2019 Financial Results
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three and 12 months ended December 31, 2019, and provided an operating forecast and program updates. Ligand... 
From Business Wire News Releases
Ligand's Technologies Support and Enable Potential Coronavirus Treatments
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that its proprietary technologies are being utilized by partners to support and enable potential treatments for the 2019 novel coronavirus,... 
From Business Wire News Releases
Lemelson Capital Management Reports FYE 2019 Results for The Amvona Fund, LP
From GlobeNewswire News Releases
Ligand Enters into OmniAb® Platform License Agreement with Pandion Therapeutics
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces it has entered into a worldwide OmniAb license agreement with Pandion Therapeutics. Under the agreement, Pandion will be able to use... 
From Business Wire News Releases
Ligand to Report 2019 Fourth Quarter and Full Year Financial Results on February 6th
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today plans to report 2019 fourth quarter and full year financial results on February 6, 2020. Ligand’s CEO John Higgins, President and COO... 
From Business Wire News Releases
Two Ligand Pharmaceuticals Board Members Recognized as 2019 Most Influential Corporate Directors by WomenInc. Magazine
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that two members of its Board of Directors, Nancy Gray and Sarah Boyce, have been named to WomenInc. magazine’s 2019 Most Influential... 
From Business Wire News Releases
Ligand Enters into Worldwide OmniAb® Platform License Agreement with Sanofi
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces it has entered into a worldwide OmniAb license agreement with Sanofi. Under the agreement, Sanofi will be able to use Ligand’s full OmniAb... 
From Business Wire News Releases
Ligand Pharmaceuticals Ranked in Deloitte’s 2019 Technology Fast 500™
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced it ranked in Deloitte’s Technology Fast 500™, a listing of the 500 fastest-growing technology, media, telecommunications, life... 
From Business Wire News Releases
< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.